Retatrutide and RAD-140 (Testolone)
No clinical trial has studied this combination. RAD-140 is not approved for human use. Retatrutide is not FDA approved. All rationale for combining them is anecdotal.
This page reviews what is known about combining retatrutide with RAD-140 (testolone): the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
SARM communities discuss RAD-140 with retatrutide for body recomposition — using retatrutide for fat loss while using RAD-140 for lean mass support. RAD-140 is considered one of the more potent SARMs for anabolic effects with purportedly lower androgenic side effects than traditional steroids. The combination is discussed anecdotally with no clinical evidence.
Human Evidence
No published clinical trial has studied retatrutide combined with RAD-140. RAD-140 itself has only limited Phase 1 human data for breast cancer treatment (not body composition). The FDA has issued safety warnings about SARMs including liver injury, heart attack, and stroke. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for the combination.
Theoretical Rationale
The theoretical rationale mirrors other SARM-GLP-1 combinations: retatrutide drives fat loss through appetite suppression and metabolic effects while RAD-140's androgen receptor agonism is hypothesized to preserve or build lean mass. This is pharmacologically speculative. The interaction between triple receptor agonism and selective androgen receptor modulation is unstudied in humans.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- RAD-140: Liver toxicity (case reports), hormonal suppression, cardiovascular effects; long-term safety unknown
- Combined: Unknown interaction risks; no safety data for the combination exists; RAD-140 is not approved for human use
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss. RAD-140 has anecdotal and limited preclinical evidence for anabolic effects. Whether RAD-140 would meaningfully preserve lean mass during retatrutide treatment is unknown. No body composition data exists for the combination.
What People Are Discussing Online
Reddit communities (r/sarmssourcetalk, r/Peptides, r/PEDs) discuss RAD-140 with retatrutide as a body recomposition stack. Common claims include superior lean mass preservation versus GLP-1 alone and accelerated fat loss. These claims are anecdotal. The FDA has specifically warned against SARMs in bodybuilding products.
Regulatory and Legal Context
RAD-140 is not approved for human use in any jurisdiction. It is sold as a research chemical. The FDA has warned that SARMs are associated with serious safety risks. Retatrutide is not FDA approved. Using two unapproved compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied this combination. RAD-140 itself has only limited Phase 1 human data. No safety or efficacy data exists for the combination.
RAD-140 is not approved for human use in any jurisdiction. It is sold as a research chemical. The FDA has warned about serious risks associated with SARMs including liver injury.
Online communities discuss this combination for body recomposition. The rationale is anecdotal and not supported by clinical evidence.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW